Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pan-tumor × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 39 Rectal Neoplasms 25 Stomach Neoplasms 21 Colorectal Neoplasms 18 Triple Negative Breast Neoplasms 13 Neoplasm Metastasis 9 Nasopharyngeal Carcinoma 8 Colonic Neoplasms 8 Locally Advanced Rectal Cancer 7 Pancreatic Neoplasms 6 Esophageal Neoplasms 6 Biliary Tract Neoplasms 6 Brain Neoplasms 5 Adenocarcinoma Of Esophagus 5 Neuroendocrine Tumors 3 Neoplasms 3 Cholangiocarcinoma 3 Anus Neoplasms 3 Advanced Solid Tumors 3 Adenocarcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasm, Residual 2 Meningeal Neoplasms 2 HER2-positive Breast Cancer 2 Gastrointestinal Neoplasms 2 Early Low Rectal Cancer 2 Colorectal Cancer Metastatic 2 Carcinoma 2

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡